Background Progressive ventricular remodeling after myocardial damage is associated with a poor prognosis. Optimal prevention of the histopathological processes involved in remodeling requires a more complete understanding of the mechanisms involved in initiating and maintaining these structural changes. Since the sympathetic nervous system and the renin-angiotensin system may be involved in the remodeling process, the structural effects of pharmacological inhibitors have been evaluated in a canine model of localized myocardial injury resulting from transmyocardial DC shock.
Methods The mechanisms initiating and contributing to progression of left ventricular (LV) remodeling have not been fully identified. The load on the LV wall resulting from intracavitary pressure and radius of curvature undoubtedly plays a role,6 but hormonal, autocrine, and paracrine factors also may be involved. [16] [17] [18] [19] Some phar-macological agents, predominantly angiotensin-converting enzyme (ACE) inhibitors, have exhibited a favorable effect on remodeling in clinical and experimental studies, 1, 4, 1114, 15, 20, 21 but the mechanism of this effect is not clear.
Norepinephrine17,22-26 and angiotensin 1119,27.28 are known stimulants of myocardial hypertrophy and also may play a role in growth of the cardiac interstitium. 18, 29, 30 Since the sympathetic nervous system and the renin-angiotensin system are activated in the setting of acute myocardial infarction,3' it is attractive to postulate that these hormones may contribute to remodeling after myocardial damage and that inhibition of these effects might attenuate the process. Indeed, a-adrenoceptor blockade has been shown to inhibit norepinephrinemediated myocyte hypertrophy,32 and ACE inhibitors are effective in preventing remodeling in experimental and clinical studies.1,4,111S521
We used a canine model of localized myocardial necrosis to explore the time course and structural changes in the myocardium during remodeling. 3152033 We have previously described the natural history of this process, which is characterized by an early increase in mass of the uninvolved myocardium associated by 16 weeks with considerable global LV dilation. 3 The present studies were undertaken to explore the effect of specific inhibitors of the actions of norepinephrine and angiotensin II on structural changes during the first 16 weeks after myocardial damage. Since inhibitors of these systems also tend to reduce blood pressure and ventricular load, hemodynamic monitoring at trough drug effect was used to gain insight into the magnitude of the chronic load reduction associated with the interventions.
Methods Myocardial Damage
Discrete transmural necrosis on the anteroapical surface of the left ventricle of the dog was produced by transmyocardial DC shock.3'33 Mongrel dogs were anesthetized with sodium pentobarbital, intubated, and prepared for the transmyocardial DC shock procedure after baseline hemodynamic measurements were made in the awake state. Animals were placed in the right lateral position. A small area of the left chest over the maximal precordial impulse was shaved. A pigtail catheter was placed across the aortic valve and then advanced 1 to 2 cm to distance it from conduction tissue at the base of the heart. A premeasured soft metallic guide wire was then passed through the catheter with approximately 5 mm of wire extended beyond the catheter tip into the LV cavity. One electrode paddle was placed on the shaved area of the left chest, and the second electrode was connected to the proximal end of the guide wire that had been placed in the left ventricle. Shocks of 80 J were delivered at 25-to 60-second intervals to a total of one shock per kilogram of body weight. This protocol was previously determined to produce a moderate-sized area of transmural necrosis involving 17±6% of the LV myocardium. 33 Heart rhythm was monitored electrocardiographically throughout the DC shock procedure. Each shock of 80 J was invariably followed by a rhythm disturbance. Usually this was a short run of nonsustained ventricular tachycardia that did not result in hemodynamic compromise. The next shock was delayed until hemodynamic parameters were stable. Rarely, cardioversion (80-J shock) was needed to break ventricular tachycardia when it was associated with low blood pressure. In these situations, this "therapeutic" cardioversion was counted as one of the individual shocks for that dog. Temporary bradyarrhythmias occasionally occurred but generally did not persist and rarely required therapy. A brief period of hypotension, occasionally associated with bradyarrhythmias, often followed an individual shock. After the completion of the shock procedure, the guide wire and catheter were removed, and hemostasis was achieved at the puncture site by pressure. The procedure usually took 30 to 45 minutes.
Experimental Protocols
This study was divided into two separate protocols. All experiments were performed in accordance with the guidelines of the University of Minnesota Animal Research Committee.
Protocol 1
Thirty-four adult mongrel dogs subjected to DC shockinduced myocardial damage were studied. Three animals did not survive the procedure. Surviving animals (mean weight, 17.1+± 1.1 kg) were randomly assigned within 24 hours to a control group (n=15), to treatment with the ACE inhibitor zofenopril (n=7), or to treatment with the a,-adrenergic blocking agent terazosin (n=9). Treatment was initiated the day after the DC shock procedure and continued for 16 weeks. It was elected to have a larger number of animals in the control group in order to confirm the reproducibility of structural changes in this model. All animals underwent baseline magnetic resonance imaging (MRI) and hemodynamic studies before transmyocardial DC shock. These studies were repeated 1 and 16 weeks after myocardial damage. Medications were withheld on the morning of hemodynamic studies at 1 and 16 weeks.
Zofenopril, a sulfhydryl group-containing ACE inhibitor that exhibits a sustained 24-hour effect on blood pressure in experimental animals, was given once daily in a morning dose of 10 mg. Terazosin was also given in a daily morning dose of 10 mg. The efficacy of the terazosin dose in attenuating the hypertensive response to phenylephrine was confirmed in 2 normal dogs before this study.
At the end of the 16-week study period, 5 terazosin-treated animals underwent phenylephrine challenge while on therapy using incremental infusion rates between 50 and 200 ,ug/min while mean arterial pressure was monitored. This challenge was performed at the same time of day as hemodynamic studies approximately 24 hours after drug dosing. Terazosin therapy was then discontinued, and 1 week later, the phenylephrine challenge was repeated at the same time of the day using the same protocol. This procedure was performed to confirm that chronic therapy with terazosin resulted in effective long-term a1-adrenoceptor blockade. No pharmacological test of the inhibiting effect of zofenopril was performed. At the end of the 16-week study period, most of the dogs were entered into other studies that precluded gross examination of the heart at the end of this protocol.
Protocol 2
Protocol 2 was started after the completion of protocol 1. Thirty-six adult mongrel dogs were studied. As in protocol 1, all underwent baseline MRI 1 week before the creation of LV damage. Baseline resting hemodynamic values were obtained before DC shock. Twenty-four hours after the induction of myocardial damage, 32 dogs (mean weight, 20 .4±0.6 kg) were assigned to one of four different groups: a control group (n=7), which received no therapy; a group treated with ramipril 10 mg BID (n=8); a group treated with low-dose ramipril 1.25 mg BID (n=8); and a group assigned to therapy with DUP 532 (n=9), an AT1-receptor blocking agent. Two dogs did not survive DC shock (procedural mortality of 5.6%) and 2 additional animals developed complete heart block as a result of DC shock and did not continue in this protocol. Pharmacological therapy was continued for a period of 16 weeks. Hemodynamic measurements and MRI scans, separated by a period of 24 to 48 hours, were repeated at 2 and 16 weeks after DC shock. During the 16-week protocol, dogs from all four groups were treated in a similar manner with respect to diet and activity level. At the end of this study period, the majority of these animals were reassigned to other studies.
Ramipril is a non-sulfhydryl-containing prodrug that is rapidly hydrolyzed after absorption to ramiprilat, its active metabolite. The At the time of initiation of protocol 2, the MRI method had changed. Magnet strength had been upgraded to 1.5 T. To increase signal-to-noise ratio, an 18-cm Helmholtz coil was used. All of the imaging sequences were synchronized to the ECG signal obtained from leads placed on the shaved skin surface of the dog. Scout images were taken in the axial plane with an ultrafast gradient echo sequence (TurboFlash). 20 The parameters for this sequence were TR/TE/angle of 6 milliseconds/3 milliseconds/and 8 degrees, respectively, and a matrix of 128*256 within a field of view of 250 mm. The delay after the inversion pulse was kept to a minimum, 15 milliseconds, resulting in a bright blood signal and a hypointense myocardium. From axial scout images, a long axis was obtained. The short-axis orientation was aligned perpendicular to the main axis of the left ventricle. Aside from providing assistance in defining the short-axis plane, the TurboFlash sequence also provided information on how many short-axis cine sequences (described below) were needed to image the myocardium from apex to base. The short-axis TurboFlash images covered the heart from apex to base using a slice thickness of 10 mm with no interslice gap.
After completion of the TurboFlash sequence, a gradient echo (FISP) cine sequence was performed to provide images from which the calculations of ventricular mass and volume were made. To improve the contrast of the cine images, a contrast agent (gadolinium-DPTA) was administered intravenously at the FDA-approved dose (0.1 mg/kg). This contrast agent enhances the blood, thus giving better wall definition. The parameters for the FISP sequence were TR/TE/angle of 30 milliseconds/10 milliseconds/60 degrees, respectively, with a matrix of 128*256 within a field of view of 250 mm. A section thickness of 10 mm with no interslice gap was used with short-axis images obtained from the apex to the base. Each myocardial level took approximately 5 minutes to image, depending on heart rate. This protocol provided high signalto-noise movielike images of the heart. LV mass and volume were calculated from end-diastolic images as in protocol 1. To calculate LV ejection fraction (LVEF), the end-systolic image was defined by scrolling through the images obtained at each tissue level (separated by 30-millisecond intervals) and noting the one with the smallest ventricular cavity. Once identified, the LVEF was calculated in a standard fashion by subtracting the total end-systolic volume of the ventricle from the total end-diastolic volume and dividing the resultant figure by the end-diastolic volume.
Mass and volume measurements were made by two of the authors, who were unaware of the treatment status of the dogs at the time of analysis. Intraobserver error and interobserver error for these individuals has been estimated previously to be less than 3 g for mass and less than 3 mL for volume in canine hearts.3
A further analysis of LV remodeling was performed in both protocols by assessing wall thickness and chamber diameter. Septal, anterior, lateral, and posterior wall thickness was measured at end diastole in all animals in each group in the third short-axis slice from the base of the heart. This slice was chosen because it was located in the midventricle and did not include the scar at the apex. Chamber diameter was also measured at this level from the endocardium of the septum to the endocardium of the lateral wall and from the endocardium of the anterior wall to the endocardium of the posterior wall. The chamber diameter to wall thickness ratio (d:h) was derived as an index of diastolic wall stress by dividing the mean of the two values for chamber diameter by the mean of the four regional measurements of wall thickness.
To ascertain whether any early structural change in the myocardium represented inflammatory fluid, T2 relaxation times were obtained during the baseline MRI study and repeated at the 1-week study in 6 control dogs in protocol 1. This parameter reflects the rate at which nuclei lose coherence with each other after the application of radiofrequency pulses.37 Alteration in the T2 relaxation time reflects change in tissue fluid content.37 This parameter was assessed in three randomly chosen areas remote from the scar tissue using a method previously described from this center. 38 The mean of the values was then calculated.
Statistical Methods
ANOVA was used to determine if changes in parameters within or between the treated or control groups were statistically significant. Based on the results of the ANOVA, intergroup and intragroup comparisons were made using paired and unpaired t tests. The obtained P values were interpreted using the modified Bonferroni method. 39 The response of mean arterial pressure to phenylephrine was assessed using a repeated two-factor ANOVA (terazosin, phenylephrine). Data are expressed as mean±t1 SD. Results
Protocol 1
Thirty-one dogs were randomized to the three treatment arms, but 2 dogs in the control group died during the first week of follow-up, 1 unexpectedly and 1 related to a complication of a procedure. The (Fig 1) . The zofenopril-treated group exhibited an insignificant increase in LV volume and no change in mass at 16 weeks. At this time point, the absolute increase in end-diastolic volume was significantly less in the zofenopril group compared with the control group, and there was significant inhibition of the increase in ventricular mass (Fig 1) .
Early Structural Changes
By 1 week after DC shock, the control group exhibited a significant increase in LV mass but not in ventricular volume (Table 1 ). This early change in mass was inhibited, as expected, by zofenopril, but also appeared to be inhibited by terazosin (Table 1 and Fig  1) . The increase in mass observed in the control group was significantly greater than the mass change observed in either of the drug-treated groups. Neither of the drug-treated groups exhibited a significant increase in ventricular volume at 1 week. The reproducibility of the structural changes in the control group in protocol 1 is demonstrated in Fig 2. WaU Thickness, Chamber Diameter, Wal Stress, and T2 
Relaxation
Changes in wall thickness and chamber diameter from baseline in protocol 1 are displayed in Table 2 and are consistent with the mass and volume data. Regional wall thickness and chamber diameter were similar at baseline in the three groups. Wall thickness increased significantly in the septal, lateral, and pos- (Table 3) . This parameter was assessed in three areas remote from the damaged zone where increased wall thickness had been documented. riod. There was a significant hemodynamic difference between the control and zofenopril groups over the 16-week period. At 16 weeks, PCWP in the zofenopril group (9±1 versus 16±1 mm Hg, P=.0005) was significantly lower than in the control animals. Arterial pressure was not significantly altered by zofenopril; there was a trend toward a reduction in this parameter at 1 week but not at 16 weeks.
Phenylephrine Challenge
The mean arterial pressure response to phenylephrine on and off terazosin therapy is shown in Fig 3. Terazosin significantly reduced the arterial pressure response to phenylephrine (P=.0025). These data indicate that terazosin, despite the lack of a sustained effect on remodeling, maintained a persistent vascular aladrenoceptor blockade with no evidence of pharmacological tolerance. Protocol 2 Thirty-two dogs survived DC shock and were randomized to treatment groups. Two did not survive the DC shock procedure, and 2 developed complete heart block and were excluded from further analysis. LV Mass and Volume LV mass and LV end-diastolic volume were similar in the four groups at baseline ( significantly less than that observed in the control, DUP 532, and low-dose ramipril groups.
LV ejection fraction was similar among the four groups at baseline (Fig 4) . In the control group, there was a reduction in the ejection fraction over the 16-week follow-up period (57±2% to 48±3%, P=.05). A similar finding was observed in dogs treated with DUP 532 (58±3% to 46±2%, P=.002). There was also a trend toward a reduction in ejection fraction in dogs receiving low-dose ramipril (56±2% to 49±3%, P=.08). A nonsignificant increase in ejection fraction was noted in those treated with high-dose ramipril (52±2% to 59±3%, P=.14), and at the end of the study period, ejection fraction was significantly greater in this group compared with control animals (59±3% versus 48±3%, P=.02), those treated with low-dose ramipril (59±3% versus 49±3%, P=.04), and those treated with DUP 532 (59±3% versus 46±2%, P=.006).
Mean wall thickness increased significantly between baseline and 2 weeks in all groups except the high-dose ramipril group (Table 6 ). This observation, along with the lack of significant change in chamber diameter during this period, is consistent with the overall mass and volume changes already described. At 16 weeks, chamber diameter had increased significantly in all groups except the high-dose ramipril group, with little further change in wall thickness. This resulted in a significant increase in the d: h ratio in the control, Intergroup comparisons revealed no signifiCant differences between groups at baseline except for HR, which was significantly higher in dogs randomized to 90±3 89±4 92±2 94±3 86±3 78±3t 89±3 93±4 91±2 80±3 § 92±2 92±4   7±1  9±1  9±1  8±1  7±1  8±1  9+1  11+1  12+1*  7-+1 § 11+1  10±1  14±1  16±1  16±1  17±1  15±1  16±1  17±1  19±1  18±2  14±1* 19±1  18±1  4±1  5±1  5±1  5±1  4±1  5±1  5±1  7±1  7±1  4±1  6±1  6±1 CO, L/min 3 To determine the degree of ACE blockade by the two doses of ramipril, angiotensin I challenge was performed on 6 control dogs, 6 dogs taking high-dose ramipril, and 7 dogs taking low-dose ramipril. These studies were performed at the end of the 16-week study period. In the dogs treated with low-dose ramipril (Fig  SA) , the arterial pressure response to the higher bolus was performed at baseline, before the initiation of therapy, and at 2 and 16 weeks after DC shock. When performed while on therapy, the angiotensin II challenge was carried out approximately 16 hours after the last dose of the drug. Therapy with DUP 532 was associated with a significant attenuation of the increase in arterial pressure in response to bolus injections of angiotensin II (Fig 6) . While it appears that some AT,-blocking activity may be lost with chronic therapy, inhibition of the systemic pressor response was still statistically significant at 16 weeks when compared with baseline and not statistically different from the degree of inhibition at 2 weeks. These data suggest that there was persistent peripheral vascular AT,-receptor blockade by DUP 532. Discussion aoses O0 angiotensin i was signincantiy innibiteU. In Structural changes that occur in the myocardium after those treated with high-dose ramipril (Fig SB) in PCWP from 5 to 30 mm Hg in this dog resulted in a 5.5-mL increase in LV volume from 72.0 to 77.5 mL. Thus, the volume increase in this model results from remodeling and cannot be attributed to an augmentation of preload.
We have previously reported an early increase in myocardial mass in this model.3,1521 The stimulus for this early structural change is unclear. Since the LV volume increase at this early time point is small, inconsistent, and not statistically significant and since an estimate of diastolic wall stress was actually reduced at 7 days, it is difficult to ascribe the mass increase to a compensatory response to an increase in chamber volume or diastolic wall stress, mechanisms thought to play a significant role in initiating remodeling. 21 The index of wall stress used in this study does not take into account LV pressure and simply reflects the association between chamber diameter and wall thickness. However, when measured at end diastole, as in this study, this index is probably a reasonable guide to diastolic load. The present experiments were designed to explore a possible role for norepinephrine and angiotensin in the LV remodeling process that follows localized myocardial damage. Two ACE inhibitors, one sulfydryl containing and one a nonsulfydryl compound, were effective in preventing both mass increase and chamber dilation over a 16-week postinjury period. In contrast, the a1-adrenoceptor blocker terazosin was ineffective by 16 weeks, although it did inhibit the early mass increase during the first week. Failure of a chronic effect of terazosin on ventricular remodeling probably cannot be attributed to tachyphylaxis, since the phenylephrine dose-response curve remained significantly shifted to the right during chronic therapy. These data suggest that norepinephrine may be involved through a-adrenoceptor stimulation in the early remodeling in this model but that long-term structural changes occur despite al-receptor inhibition. On the contrary, ACE inhibitors are effective in blocking both the early and long-term process.
The second protocol in these studies was designed to further elucidate the mechanism of ACE inhibitor effect on remodeling. Since load reduction, decreased angiotensin II formation, and increased kinin production all may accompany ACE inhibitor therapy, studies were performed with the angiotensin receptor antagonist DUP 532 as well as with low-dose ramipril that was ineffective in lowering arterial pressure. The latter strategy was based on the results of previous studies in a rat aortic coarctation model in which ramipril or enalapril inhibited LV hypertrophy in a low dose that exerted no blood pressure-lowering effect.4344 Although the mechanism of this action was not clarified in those studies, a direct hormonal effect was considered. 43 ACE inhibition is well known also to inhibit bradykinin degradation. Bradykinin, like other endogenous vasodilators that act through the production of nitric oxide and the intracellular second messenger cGMP,51-53 may have antigrowth effects unrelated to load reduction. In support of this hypothesis are data demonstrating that the addition of a bradykinin antagonist to ACE inhibitor therapy results in loss of the usual ACE inhibitor antiremodeling effect after intimal injury.53 Moreover, preliminary data from the rat coarctation model demonstrate that a bradykinin antagonist blocks the antihypertrophic effect of ramipril.54 Therefore, it is possible, although not yet proved, that the antiremodeling effect of ACE inhibitor therapy may be related to an increment in bradykinin. Analysis of the effect of a bradykinin antagonist on the antiremodeling action of an ACE inhibitor compound in this model would provide important data on this question.
These studies were not designed to quantitate the (Table 2) , further supporting the concept that attenuation of ventricular remodeling is accompanied by a reduction in wall stress. The response of the remodeled and remodeling-inhibited ventricles to exercise stress must be studied in order to evaluate the long-term effects in this model.
The morphometric correlates of remodeling and its inhibition in this model were not addressed in this study. Accordingly, the relative contribution of myocyte hypertrophy or shape change and growth of the cardiac interstitium to the remodeling process are unclear. However, the major end points of these studies were the changes that occurred in ventricular mass and volume, parameters that we3,20 and others3536 have shown can be very accurately assessed by MRI. Ongoing and future studies will address the morphometrics of remodeling in this model.
Summary
The data from this study confirm previous observations from this laboratory that ventricular remodeling occurs after transmyocardial DC shock and that these structural changes are associated with a modest reduction in LV systolic function. Despite attenuating the early mass increase, a1-adrenergic blockade was ineffective in preventing long-term remodeling in this model. Conversely, two converting enzyme inhibitors were effective in preventing remodeling. The failure of lowdose ramipril and AT,-receptor blockade to inhibit remodeling suggests that angiotensin II acting through the AT1-receptor may not be critical for the remodeling process, although load reduction from ACE inhibition may contribute to the antiremodeling effect. and a grant from Hoechst Pharmaceuticals. We wish to thank Tracy Elbers and Lynn Hartman for their technical assistance in performing these studies and Andrea Dahl for her assistance in preparation of the manuscript. We also wish to thank DuPont Pharmaceutical Co for providing DUP 532, Squibb Pharmaceutical Co for providing zofenopril, and Hoescht Pharmaceutical Co for providing ramipril for this study.
